Rosetta Genomics signed an agreement with Columbia University Medical Center to advance its lead cancer diagnostic for cancer of unknown primary (CUP).
"Our proprietary diagnostic protocol for CUP has demonstrated encouraging results in terms of the large number of cancers which we may be able to identify from the metastases as well as the overall high accuracy of the test," states Dalia Cohen, Ph.D., Rosetta Genomics, global head of R&D.
Rosetta Genomics says that this is its first agreement for clinical validation of one of its cancer diagnostic tests. The company is developing several microRNA-based diagnostics.
Rosetta Genomics’ CUP diagnostic, currently in the final stages of development, is designed to assist clinicians in identifying the origin of tumors that have metastasized throughout the body.
Under the terms of the agreement, Rosetta Genomics will provide Columbia University Medical Center with its protocol for diagnosing the primary origin of metastatic cancers. The tool will then be tested and validated using unknown samples provided by the medical center.